PROGESTOGEN THERAPY FOR DES-INDUCED CV ABNORMALITIES

临床证据表明，孕酮可能会减少 已烯雌酚生殖道腺病的存在 （DES）暴露的人类女性。 测试的功效 孕酮治疗暴露于DES的人类女性， 在这项研究中提出使用经雌激素处理的小鼠 作为模型系统。 新生雌性BALB/c小鼠将接受 皮下注射1或25 μ g雌二醇（E2）， 从出生后24小时开始。 老鼠会断奶 在25天时，随机分布在以下人群中： 实验组：A）不接受进一步治疗的动物， B）接受高剂量Provera（R，C）的那些 高剂量Provera（R）和炔雌醇-17，和D）那些 仅接受炔雌醇17B。 所有团体将收到 通过硅橡胶植入物进行正常治疗。 治疗将开始于 两个月的年龄，并将持续一年。 小鼠免受 每隔三个月， 阴道涂片连续10天，然后处死。 冷冻一半的宫颈阴道（CV）道，然后 分析细胞质和细胞核P受体的存在 (PR)和E（ER）受体。 CV束的另一半也将 冷冻切片进行组织学检查。

Clinical evidence suggests that progesterone may reduce the presence of adenosis in the genital tracts of diethylstilbestrol (DES)-exposed human females. Testing of the efficacy of progesterone therapy for the DES exposed human female is proposed in this study using the neonatally estrogen treated mouse as the model system. Neonatal female BALB/c mice will receive subcutaneous injections of 1 or 25 ug of estradiol (E2) for five days beginning 24 hours following birth. The mice will be weaned at 25 days and randomly distributed among the following experimental groups: A) animals receiving no further treatment, B) those receiving a high dose of Provera (R, C) those receiving a high dose of Provera (R) and ethinyl-estradiol-17, and D) those receiving ethinyl-estradiol 17B only. All groups will receive normonal treatment via silastic implants. Treatment will begin at two months of age and will continue for one year. Mice from each group will be selected at three month intervals and subjected to vaginal smears for ten consecutive days followed by sacrifice. One half of the cervicovaginal (CV) tract will be frozen and then analyzed for the presence of cytoplasmic and nuclear P receptor (PR) and E (ER) receptor. The other half of the CV tract will also be frozen and sectioned for histologic examination.